SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)

Core Insights - SCYNEXIS, Inc. is presenting data on its second-generation fungerp drug candidate, SCY-247, at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) from January 28 to 30, 2026, in Las Vegas, Nevada [1][2] - The company emphasizes the potential of SCY-247 as a critical weapon against drug-resistant fungal infections, highlighting its potent antifungal activity and favorable safety profile observed in clinical investigations [2][4] - IMARI is a joint conference organized by the American Society for Microbiology and the Infectious Diseases Society of America, focusing on the challenge of antimicrobial resistance [3] Company Overview - SCYNEXIS, Inc. is a biotechnology company focused on developing innovative medicines to combat difficult-to-treat infections, particularly those that are increasingly drug-resistant [4] - The company’s antifungal platform, "fungerps," includes Ibrexafungerp, which has been approved by the FDA for treating vulvovaginal candidiasis and reducing recurrent cases [4] - SCY-247 is currently in clinical development and has received QIDP and Fast Track designations from the FDA, with additional antifungal assets in pre-clinical and discovery phases [4]